Abstract
The present Industry Update covers the period 16 July–15 August 2011, with information sourced from company press releases, media newswires, regulatory agencies and relevant patent offices. The restructuring announced by Merck was not unexpected but its adverse effects will be keenly felt by employees, particularly in the USA. The approval of Pradaxa™ in Europe is welcome and likely to provide a significant clinical benefit. Reports of Phase III clinical studies were few in number, however some exciting early stage research was reported, most notably in relation to the potential development of broad-spectrum antiviral therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
